Determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in normal lung parenchyma as quantified on high- resolution CT (HRCT) imaging analysis, pooling subjects on a stable dose of pirfenidone or nintedanib with subjects not on other treatment for IPF.
The PI of this project was: Keith Meyer, MD
This project was funded by: Promedior
The term of this project was: August 2016 to August 2020
The number of subjects scanned during this project was: 10